FDA's Final Rule on Laboratory-Developed Tests: What Is the Impact on Clinical Pharmacogenomics in the United States?
J Appl Lab Med
.
2024 Oct 4:jfae105.
doi: 10.1093/jalm/jfae105.
Online ahead of print.
Authors
Xander M R van Wijk
1
,
Gwendolyn A McMillin
2
3
Affiliations
1
Owner and Principal Consultant, van Wijk Consulting LLC, Houston, TX, United States.
2
Professor, Department of Pathology, University of Utah Health, Salt Lake City, UT, United States.
3
Medical Director of Clinical Toxicology, Scientific Director of Mass Spectrometry, ARUP Laboratories, Salt Lake City, UT, United States.
PMID:
39365749
DOI:
10.1093/jalm/jfae105
No abstract available